Healthcare
QSAM
Coming October 18, 2023
QSAM Biosciences is developing next-generation nuclear medicines for the treatment of cancer and other diseases.
Menu
QSAM Biosciences is developing next-generation nuclear medicines for the treatment of cancer and other diseases.
MAIA Biotechnology received preliminary data from its Phase 2 Clinical trial and the results are very promising.
The Lumicell Direct Visualization System assists surgeons to detect cancerous tissue in real time so they can remove it all the first time.
Gain is ready to move into a Phase 1 clinical trials for with a novel small-molecule treatment for Parkinson’s disease.
Kineta, Inc. (Nasdaq: KA), announced today the achievement of a development milestone which triggers a $5 million payment from its research and development collaboration with Merck
Join our fireside chat to get a physician’s perspective on pain management and the effect on patients when they are introduced to opioids
Spire Health’s remote respiratory monitoring system reduces hospitalizations 65% and saves payers $10,000 per member annually
bit.bio has the ability to create any human cell type and to manufacture it at scale with precision and consistency
MAIA and Regeneron are evaluating THIO with Libtayo in a Phase 2 clinical trial for Non-Small Cell Lung Cancer.
How Kineta’s partnership with Merck could alter the future of cancer therapy by solving the challenge immuno-suppression
1460 Broadway
New York, NY 10036
(917) 747-6198
© Copyright 2021 FORCE Family Office